Article

Real-life use of ropeg-interferon α2b in Polycythemia Vera: patient selection and clinical outcomes

2024-04-09

Abstract excerpt

<title>Abstract</title> <p>Background Ropeginterferon-alfa2b (ropegIFNα2b) is a long-acting IFN formulation with broad FDA/EMA approval as a therapy of polycythemia vera (PV) with no symptomatic splenomegaly. There is currently lack of information on the real-world patient selection, including the impact of local reimbursement policies, and drug management, particularly: type/timing of screening and follow-up te...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0104f471-9a7c-539b-81c6-aff520e2274b
DOI: 10.21203/rs.3.rs-4136096/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Real-life use of ropeg-interferon α2b in Polycythemia Vera: patient selection and clinical outcomesDOI 10.21203/rs.3.rs-4136096/v1Read

Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.Semantic proximity Read

Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera.Semantic proximity Read

A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.Semantic proximity Read

Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.Semantic proximity Read

Real-world experience with Ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms.Semantic proximity Read

Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study.Semantic proximity Read

[Sustained hematologic complete response after discontinuation of ropeginterferon alfa-2b in patients with polycythemia vera].Semantic proximity Read

Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C.Semantic proximity Read

Pegylated interferon: the who, why, and howSemantic proximity Read

A real-world analysis of polycythemia vera at two comprehensive cancer centers in Cali, Colombia.Semantic proximity Read

Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera TreatmentSemantic proximity Read

Tolvaptan in ADPKD Beyond Trials: Tolerability, Monitoring, and Real-World OutcomesSemantic proximity Read